Atopic Dermatitis

Ruxolitinib was associated with clinically meaningful improvement in itch in a cohort of patients with atopic dermatitis, according to a study.

Cyclosporine and dupilumab may show more effectiveness up to 16 weeks in treating atopic dermatitis than methotrexate and azathioprine, according to a systematic review and network meta-analysis.

Patients with cutaneous immune-mediated diseases, such as psoriasis, atopic dermatitis and hidradenitis suppurativa, may not have an increased risk for developing severe COVID-19, based on available data from the current and previous coronavirus outbreaks.

Kubota Vision and Leo Pharma have entered into an open innovation agreement to screen novel vascular adhesion protein-1 inhibitor compounds, according to a press release.

Leo Pharma, Oneness Biotech and Microbio Shanghai have entered into a worldwide exclusive licensing agreement for FB825, a novel atopic dermatitis and allergic asthma drug candidate, according to a press release.

Crisaborole ointment was well tolerated and effective in treating infants with mild to moderate atopic dermatitis, according to findings published in American Journal of Clinical Dermatology.

The FDA approved Pfizer’s supplemental new drug application for Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis, or AD.

MIAMI BEACH, Fla. — JAK inhibitors are being studied to treat patients with psoriasis and atopic dermatitis, with many showing promising outcomes, according to a presenter at South Beach Symposium.

The novel interleukin 13 inhibitor lebrikizumab improved skin lesions, pruritis and quality of life among adults with moderate to severe atopic dermatitis, according to data from a phase 2b trial published in JAMA Dermatology.

A meta-analysis of efficacy and safety findings for atopic dermatitis showed that comparing therapeutic options was difficult due to differing study methodologies and a lack of head-to-head trials.